CompanyANVSNYSEMalvern, PA

Annovis Bio Inc.

Annovis Bio develops buntanetap, an oral small molecule that inhibits translation of neurotoxic proteins including APP, amyloid beta, tau, alpha-synuclein, and TDP-43.

Stories only

SEC EDGAR ClinicalTrials.gov annovisbio.com

DEF 14ASep 11Latest SEC filing, period to Oct 14

Aug 14Latest story

August 2026

Annovis completes enrollment in Phase 3 Alzheimer's trial of buntanetap

Aug 14Quarterly updateAnnovis Bio Inc.

Annovis Bio registers long-term safety study of buntanetap in Alzheimer's disease

Aug 11Trial updateAnnovis Bio Inc.

July 2026

Annovis Bio completes enrollment in Phase 3 buntanetap trial for early Alzheimer's

Jul 9Clinical readoutAnnovis Bio Inc.